Biotech Values

[vinmantoo]

All told, investors should expect ENTA to need at least two years from the FDA’s IND acceptance to the NDA submission. (The EUA path may no longer be available by then.)

Still, even at a slower development pace, EDP-235 could be an immensely valuable asset.

Dew, that seems like a reasonable estimate. I will point out that ENTA's EDP-235 could provide great value to ENTA well before approval. If the early trials show excellent efficacy and safety then ENTA then you can be sure they will be able to find a partner to complete development and strike a good deal at better terms than they got for their Hep-C drugs. Obviously final FDA approval would be required for maximum benefits for ENTA and ENTA shareholders.